The relationship between adiposity and gleason score in men with localized prostate cancer

Prostate

Volumn 70, Issue 15, 2010, Pages 1683-1691

  Hack, Erica E ^a   Siemens, D Robert ^b   Groome, Patti A ^a  

^a QUEEN S UNIVERSITY   (Canada)

^b QUEEN S UNIVERSITY   (Canada)

Author keywords

Body mass index; Population based; Prostate cancer aggression; Type II diabetes

Indexed keywords

ADULT; AGED; ARTICLE; BODY MASS; CANCER LOCALIZATION; CANCER PATIENT; COHORT ANALYSIS; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTCOME ASSESSMENT; PHENOTYPE; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; PROSTATE CANCER; BLOOD; CHI SQUARE DISTRIBUTION; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; RETROSPECTIVE STUDY;

PROSTATE SPECIFIC ANTIGEN;

ADIPOSITY; AGED; AGED, 80 AND OVER; BODY MASS INDEX; CHI-SQUARE DISTRIBUTION; CROSS-SECTIONAL STUDIES; HUMANS; MALE; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 77958500065     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.21203     Document Type: Article

References (45)

1. Nomura A,. Body size and prostate cancer. Epidemiol Rev 2001; 23 (1): 126 -131.
2. Giovannucci E, Rimm EB, Liu Y, Leitzmann M, Wu K, Stampfer MJ, Willett WC,. Body mass index and risk of prostate cancer in U.S. health professionals. J Natl Cancer Inst 2003; 95 (16): 1240 -1244.
3. Porter MP, Stanford JL,. Obesity and the risk of prostate cancer. Prostate 2005; 62 (4): 316 -321.
4. Ma J, Haojie L, Giovannucci E, Mucci L, Qiu W, Nguyen PL, Gaziano JM, Pollak M, Stampfer MJ,. Prediagnostic body-mass index, plasma C-peptide concentration, and prostate cancer-specific mortality in men with prostate cancer: A long-term survival analysis. Lancet Oncol 2008; 9 (11): 1039 -1047.
5. Wright ME, Chang SC, Schatzkin A, Albanes D, Kipnis V, Mouw T, Hurwitz P, Hollenbeck A, Lietzmann MF,. Prospective study of adiposity and weight change in relation to prostate cancer incidence and mortality. Cancer 2007; 109 (4): 675 -684.
6. Andersson SO, Wolk A, Bergstrom R, Adami HO, Engholm G, Englund A, Nyren O,. Body size and prostate cancer: A 20-year follow-up study among 135,006 Swedish construction workers. J Natl Cancer Inst 1997; 89: 385 -389.
7. Snowdon DA, Phillips RL, Choi W,. Diet, obesity and risk of fatal prostate cancer. Am J Epidemiol 1984; 120: 244 -250.
8. Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, Chan JM, Anast JW, Carroll PR, Kane CJ,. Impact of obesity on prostate cancer recurrence after radical prostatectomy: Data from CaPSURE. Urology 2005; 66: 1060 -1065.
9. Gong Z, Agaliliu I, Lin DW, Stanford JL, Kristal AR,. Obesity is associated with increased risks of prostate cancer metastasis and death after initial cancer diagnosis in middle-aged men. Cancer 2007; 109: 1192 -1202.
10. Rodriguez C, Patel AV, Calle EE, Jacobs EJ, Chao A, Thun MJ,. Body mass index, height and prostate cancer mortality in two large cohorts of adult men in the United States. Cancer Epidemiol Biomarkers Prev 2001; 10: 345 -353.
11. Hoffman MA, DeWolf WC, Morgentaler A,. Is low serum testosterone a marker for high grade prostate cancer? J Urol 2000; 163 (3): 824 -827.
12. Schneider HJ, Sievers C, Klotsche J, Bahler S, Pittrow D, Lehnert H, Wittchen H, Stalla GK,. Prevalence of low male testosterone levels in primary care in Germany: Cross-sectional results from the DETECT study. Clin Endocrinol 2009; 70 (3): 446 -454.
13. Esteghamati A, Khalilzadeh O, Anvari M, Ahadi MS, Abbasi M, Rashidi A,. Metabolic syndrome and insulin resistance significantly correlate with body mass index. Arch Med Res 2008; 39 (8): 803 -808.
14. Nandeesha H,. Insulin: A novel agent in the pathogenesis of prostate cancer. Int Urol Nephrol 2009; 41 (2): 267 -272.
15. Graham TR, Zhau HE, Odero-Marah VA, Osunkoya AO, Kimbro KS, Tighiouart M, Liu T, Simons JW, O'Regan RM,. Insulin-like growth factor-I dependent up-regulation of ZEB1 drives epithelial-to-mesenchymal transition in human prostate cancer cells. Cancer Res 2008; 68 (7): 2479 -2488.
16. Cox ME, Gleave ME, Zakikhani M, Bell RH, Piura E, Vickers E, Cunningham M, Larsson O, Fazli L, Pollak M,. Insulin receptor expression by human prostate cancers. Prostate 2009; 69 (1): 33 -40.
17. Cassidy A, Skidmore P, Rimm EB, Welch A, Fairweather-Tait S, Skinner J, Burling K, Richards JB, Spector TD, MacGregor AJ,. Plasma adiponectin concentrations are associated with body composition and plant-based dietary factors in female twins. J Nutr 2009; 139: 353 -358.
18. Sher DJ, Oh WK, Jacobus S, Regan MM, Lee G, Mantzoros C,. Relationship between serum adiponectin and prostate grade. Prostate 2008; 68 (14): 1592 -1598.
19. Mackillop WJ, Fu H, Quirt CF, Dixon P, Brundage M, Zhou Y,. Waiting for radiotherapy in Ontario. Int J Radiat Oncol Biol Phys 1994; 30: 221 -228.
20. Mackillop WJ, Zhang-Salomons J, Groome PA, Paszat L, Holowaty E,. Socioeconomic status and cancer survival in Ontario. J Clin Oncol 1997; 15 (4): 1680 -1689.
21. Gleason DF,. Histologic grading of prostate cancer: A perspective. Hum Pathol 1992; 23 (3): 273 -279.
22. Chism DB, Hanlon AL, Troncoso P, Al-Saleem T, Horwitz EM, Pollack A,. The Gleason score shift: Score four and seven years ago. Int J Radiat Oncol Biol Phys 2003; 56 (5): 1241 -1247.
23. Greene FL, Page DI, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M, editors. AJCC Cancer Staging Manual, 6th edition. New York: Springer; 2002.
24. Health Canada. Canadian guidelines for body weight classification in adults. Ottawa: Minister of Public Works and Government Services Canada; 2003.
25. Hudson C, Fortin M, Soubhi H,. Abbreviated guidelines for scoring the Cumulative Illness Rating Scale (CIRS) in family practice. J Clin Epidemiol 2007; 60: 212.
26. SAS Institute, Inc. SAS Version 9.1. Cary, NC: SAS Institute, Inc.; 2003.
27. Newman SC, Miller AB, Howe GR,. A study of the effect of weight and dietary fat on breast cancer survival time. Am J Epidemiol 1986; 123 (5): 767 -774.
28. Freedland SJ, Isaacs WB, Mangold LA, Yiu SK, Grubb KA, Partin AW, Epstein JI, Walsh PC, Platz EA,. Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res 2005; 11 (8): 2883 -2888.
29. Pruthi RS, Swords K, Schultz H, Carson CC, Wallen EM,. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme. J Urol 2009; 181: 574 -578.
30. Freedland SJ, Wen J, Wuerstle M, Shah A, Lai D, Moalej B, Atala C, Aronson WJ,. Obesity is a significant risk factor for prostate cancer at the time of biopsy. Urology 2008; 72: 1102 -1105.
31. Kobayashi T, Mistumori K, Nishizawa K, Kawahara T, Ogura K, Ide Y,. Association between body mass index and prostate cancer detection rates in Japanese urologic patients. Urology 2005; 66: 130 -134.
32. Freedland SJ, Banez LL, Sun LL, Fitzsimons NJ, Moul JW,. Obese men have higher-grade and larger tumors: An analysis of the Duke prostate cancer database. Prostate Cancer Prostatic Dis 2009; 12: 259 -263.
33. Freedland SJ, Terris MK, Platz EA, Presti JC,. Body mass index as a predictor of prostate cancer: Development versus detection on biopsy. Urology 2005; 66: 108 -113.
34. Chan JM, Latini DM, Cowan J, DuChane J, Carroll PR,. History of diabetes, clinical features of prostate cancer, and prostate cancer recurrence-data from CaPSURE. Cancer Causes Control 2005; 16: 789 -797.
35. Ripple MO, Henry WF, Rago RP, Wilding G,. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 1997; 89 (1): 40 -48.
36. Winters SJ, Krishnasamy S,. Low testosterone in obesity and type 2 diabetes. In:, Davies TF, editor. A case-based guide to clinical endocrinology. New York, NY: Humana Press; 2008. pp 253 -262.
37. Gann PH, Hennekins CH, Ma J, Longcope C, Stampfer MJ,. Prospective study of sex hormone levels and risk of prostate cancer. J Natl Cancer Inst 1996; 88: 1118 -1126.
38. Kasper JS, Giovannucci E,. A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2006; 15 (11): 2056 -2062.
39. Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Willett W,. Height, body weight, and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 1997; 6: 557 -563.
40. Engeland A, Tretli S, Bjarge T,. Height, body mass index, and prostate cancer: A follow up of 950,000 Norwegian men. Br J Cancer 2003; 89 (7): 1237 -1242.
41. Statistics Canada: National Population Healthy Survey, 1994/95, 1996/97 and 1998/99. Catalogue No. 82-221, Vol. 2005, No. 1.
42. Rodriguez C, Freedland SJ, Deka A, Jacobs EJ, McCullough ML, Patel AV, Thun MJ, Calle EE,. Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. Cancer Epidemiol Biomarkers Prev 2007; 16 (1): 63 -69.
43. Pu YF, He HB, Zhao ZG, Chen J, Ni YX, Zhong J, Liu HY, Yan ZC, Zhu ZM,. Evaluation of visceral adipose in abdominal obesity and its clinical application. Zhonghua Yi Xue Za Zhi 2008; 88 (34): 2391 -2394.
44. Gallina A, Karakiewicz PI, Hutterer GC, Chun FK-H, Briganti A, Walz J, Antebi E, Shariat SF, Suardi N, Graefen M, Erbersdobler A, Salonia A, Rigatti P, Huland H, Montorsi F,. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. Int J Cancer 2007; 121: 791 -795.
45. Amling C, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance RS, Friedrichs PA, Moul JW,. Relationship between obesity and race in predicting adverse pathologic variables in patients undergoing radical prostatectomy. Urology 2001; 58: 723 -728.